HUP9901901A2 - Vaccines against hepatitis c - Google Patents

Vaccines against hepatitis c

Info

Publication number
HUP9901901A2
HUP9901901A2 HU9901901A HUP9901901A HUP9901901A2 HU P9901901 A2 HUP9901901 A2 HU P9901901A2 HU 9901901 A HU9901901 A HU 9901901A HU P9901901 A HUP9901901 A HU P9901901A HU P9901901 A2 HUP9901901 A2 HU P9901901A2
Authority
HU
Hungary
Prior art keywords
hepatitis
molasses
vaccines against
oil
against hepatitis
Prior art date
Application number
HU9901901A
Other languages
Hungarian (hu)
Inventor
Teresa Cabezon Silva
Nathalie Marie-Josephe Claude Garcon
Patricia Marie Momin
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of HUP9901901A2 publication Critical patent/HUP9901901A2/en
Publication of HUP9901901A3 publication Critical patent/HUP9901901A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány vakcinakőmpőzícióra vőnatkőzik, amely QS21-et, 3-De-O-acetilezett mőnőfőszfőril-lipid A-t (3D-MPL), őlaj a vízben eműlziót,amely metabőlizálható őlajból, a-tőkőferőlból és Tween 80-ból áll,valamint a következő imműnőgének közül legalább egyet tartalmaz: (a)hepatitisz C vírűs magprőtein vagy annak imműnőgén származéka, (b)hepatitisz C vírűs bűrőkprőtein vagy annak imműnőgén származéka. ŕThe invention is based on a vaccine formulation containing QS21, 3-De-O-acetylated molassespheryl lipid A (3D-MPL), an oil-in-water emulsion consisting of metabolizable molasses oil, a-molasses and Tween 80, as well as the following immunogens contains at least one of: (a) hepatitis C virus core protein or its immunogenic derivative, (b) hepatitis C virus skin protein or its immunogenic derivative. ŕ

HU9901901A 1995-06-29 1996-06-20 Vaccines against hepatitis c HUP9901901A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9513261.9A GB9513261D0 (en) 1995-06-29 1995-06-29 Vaccines

Publications (2)

Publication Number Publication Date
HUP9901901A2 true HUP9901901A2 (en) 1999-09-28
HUP9901901A3 HUP9901901A3 (en) 2000-03-28

Family

ID=10776867

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901901A HUP9901901A3 (en) 1995-06-29 1996-06-20 Vaccines against hepatitis c

Country Status (15)

Country Link
EP (1) EP0835318A2 (en)
JP (1) JPH11508769A (en)
KR (1) KR19990028505A (en)
AU (1) AU6304996A (en)
BR (1) BR9609258A (en)
CA (1) CA2222456A1 (en)
CZ (1) CZ422397A3 (en)
GB (1) GB9513261D0 (en)
HU (1) HUP9901901A3 (en)
IL (1) IL122589A0 (en)
NO (1) NO976060L (en)
PL (1) PL324906A1 (en)
TR (1) TR199701713T1 (en)
WO (1) WO1997001640A2 (en)
ZA (1) ZA965459B (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ATE357526T1 (en) * 1998-08-21 2007-04-15 Us Gov Health & Human Serv MODIFIED HCV PEPTIDE VACCINES
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
MXPA03003690A (en) 2000-10-27 2004-05-05 Chiron Spa Nucleic acids and proteins from streptococcus groups a b.
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
EP1481006A2 (en) * 2002-03-04 2004-12-01 Zagyansky, Yuly Universal antimicrobial treatment
JP2005535308A (en) 2002-06-13 2005-11-24 カイロン コーポレイション HML-2 polypeptide expression vector
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
DE60332477D1 (en) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic UNEXPECTED SURFACE PROTEINS IN NEISSERIA MENINGITIDIS
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102302776B (en) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 Injectable vaccines against multiple meningococcal serogroups
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PT1631264E (en) 2003-06-02 2009-11-03 Novartis Vaccines & Diagnostic Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0415025A (en) 2003-10-02 2006-12-12 Chiron Srl liquid vaccines for multiple meningococcal serogroups
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
RU2379052C2 (en) 2004-04-30 2010-01-20 Чирон С.Р.Л. Meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
JP2008508320A (en) 2004-07-29 2008-03-21 カイロン コーポレイション Immunogenic composition against gram positive bacteria such as STREPTOCOCCUSAGALACTIAE
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CA2590974C (en) 2005-01-27 2017-10-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
EP2064230A2 (en) 2006-08-16 2009-06-03 Novartis AG Immunogens from uropathogenic escherichia coli
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN101969992B (en) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
MX337723B (en) 2008-12-09 2016-03-15 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE.
CN102481349B (en) 2009-01-12 2014-10-15 诺华股份有限公司 Cna_b domain antigens in vaccines against gram positive bacteria
CA2754618A1 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
EP2510947B1 (en) 2009-04-14 2016-02-10 GlaxoSmithKline Biologicals SA Compositions for immunising against Staphylococcus aureus
BRPI1014494A2 (en) 2009-04-30 2016-08-02 Coley Pharm Group Inc pneumococcal vaccine and its uses
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
ES2662716T3 (en) 2009-07-07 2018-04-09 Glaxosmithkline Biologicals Sa Preserved immunogens of Escherichia coli
CN102770443A (en) 2009-07-16 2012-11-07 诺华有限公司 Detoxified escherichia coli immunogens
IN2012DN00446A (en) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
NZ598458A (en) 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2846746A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
MY157607A (en) * 2009-09-10 2016-06-30 Merial Inc New vaccine formulations comprising saponin-containing adjuvants
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CN102762224A (en) 2009-12-22 2012-10-31 塞尔德克斯医疗公司 Vaccine compositions
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
EP2591097A1 (en) 2010-07-06 2013-05-15 Novartis AG Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EA025152B1 (en) 2010-12-02 2016-11-30 Бионор Иммуно Ас Peptide scaffold design
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (en) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 Method for preparing glycoprotein glycoconjugate
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
AU2013224026A1 (en) 2012-02-24 2014-08-21 Novartis Ag Pilus proteins and compositions
KR102139959B1 (en) 2012-04-26 2020-08-04 노파르티스 아게 Antigens and antigen combinations
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
HUE044612T2 (en) 2012-05-04 2019-11-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2820898T3 (en) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Meningococcal serogroup X conjugate
KR20150018870A (en) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 Peptides derived from viral proteins for use as immunogens and dosage reactants
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US20160101187A1 (en) 2012-10-02 2016-04-14 Novartis Ag Nonlinear saccharide conjugates
CN104582718B (en) 2012-10-03 2017-10-24 诺华股份有限公司 Immunogenic composition
WO2014083060A2 (en) 2012-11-30 2014-06-05 Novartis Ag Pseudomonas antigens and antigen combinations
JP2016520077A (en) 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ E1E2HCV vaccine and method of use
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
NZ766444A (en) 2014-07-23 2024-01-26 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
PT3244917T (en) 2015-01-15 2023-05-31 Pfizer Immunogenic compositions for use in pneumococcal vaccines
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
SG10202005253TA (en) 2015-07-21 2020-07-29 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
KR102459629B1 (en) 2017-01-20 2022-10-28 화이자 인코포레이티드 Immunogenic compositions for use in pneumococcal vaccines
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
JP2021534761A (en) 2018-08-23 2021-12-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic proteins and compositions
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (en) 2019-02-22 2023-03-28 ファイザー・インク Method for purifying bacterial polysaccharides
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Escherichia coli compositions and methods thereof
US20220380769A1 (en) 2020-01-24 2022-12-01 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
CN115362177A (en) 2020-02-21 2022-11-18 辉瑞公司 Purification of saccharides
JP2023514697A (en) 2020-02-23 2023-04-07 ファイザー・インク E. coli composition and method
AU2021368151A1 (en) 2020-10-27 2023-06-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024507828A (en) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Group B meningococcal recombinant vaccine
US20220387613A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
DE4041304A1 (en) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw POLYPEPTIDES DERIVED FROM STRUCTURAL PROTEINS OF HEPATITIS C-VIRUS, TEST KITS CONTAINING THESE POLYPEPTIDES AND VACCINE AGAINST INFECTIONS FROM HEPATITIS C VIRUSES
ES2188583T3 (en) * 1991-06-24 2003-07-01 Chiron Corp POLYPEPTIDES FOR HEPATITIS C VIRUS (HCV).
MA22842A1 (en) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog PROCESS FOR THE PREPARATION OF VACCINE COMPOSITIONS.
PL170980B1 (en) * 1992-06-25 1997-02-28 Smithkline Beecham Biolog Vaccine
JPH06279500A (en) * 1992-09-30 1994-10-04 Imuno Japan:Kk Hbc fused protein particle and its production
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
KR19990028505A (en) 1999-04-15
EP0835318A2 (en) 1998-04-15
TR199701713T1 (en) 1998-05-21
ZA965459B (en) 1997-04-01
AU6304996A (en) 1997-01-30
IL122589A0 (en) 1998-06-15
GB9513261D0 (en) 1995-09-06
JPH11508769A (en) 1999-08-03
BR9609258A (en) 1999-05-11
NO976060L (en) 1998-02-17
PL324906A1 (en) 1998-06-22
NO976060D0 (en) 1997-12-23
HUP9901901A3 (en) 2000-03-28
CZ422397A3 (en) 1998-06-17
CA2222456A1 (en) 1997-01-16
MX9710523A (en) 1998-09-30
WO1997001640A2 (en) 1997-01-16
WO1997001640A3 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
HUP9901901A2 (en) Vaccines against hepatitis c
ATE264691T1 (en) NEWCASTLE DISEASE VIRUS COMBINATION VACCINE
NO982497D0 (en) Vaccine compositions for ingestion through the nose
DE69426077D1 (en) ADJUVANTIES FOR VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS
DK1149589T3 (en) Protein adjuvants
PT98156A (en) A PROCESS FOR PREPARING A VACCINE COMPOSITION
NZ510419A (en) A vaccine adjuvant that is an oil-in-water immunoslimulant emulsion
ES533111A0 (en) A METHOD OF PREPARING A LIVING VACCINE
DK0792165T3 (en) Immunogenic Preparations
ES2097840T3 (en) VACCINE ADJUVANT INCLUDING A TETRAPOLIOL.
HUP0104881A2 (en) Method to produce inactivated w/o emulsion adjuvated vaccines
BR9704879A (en) Vaccine composition and use of a live cav virus
NL990018I1 (en) Vaccine against Pasteurella.
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
AR002725A1 (en) VACCINE OF VARIOUS COMPONENTS CONTAINING CLOSTRIDIAL AND NON-CLOSTRIDIAL ORGANISMS IN A SMALL DOSE FOR RUMINANTS AND A PROCEDURE FOR SUPREPARATION
HUP9801917A2 (en) Immunogenic construct, process for its preparation and use as a vaccine
BR9606725A (en) Vaccine for administration via mucosa effective for the protection of chickens against the drop in performance use of a live attenuated agent of chicken anemia and process for the protection of chickens against the drop in performance
FR2715304B1 (en) Anti-allergic vaccine.
ATE17576T1 (en) 4-PHENYL-QUINAZOLINE DERIVATIVES ACTIVE ON THE CENTRAL NERVOUS SYSTEM.
DK0729509T3 (en) Vaccine against mumps containing a Jeryl-Lynn virus strain
DE69228063D1 (en) ATTENUATED RE-MUTURED VIRUS VACCINE AGAINST MAREKS DISEASE SEROTYPE-1
ATE15501T1 (en) VACCINE FOR POULTRY AGAINST CONTAGIOUS BRONCHITIS, COMPOSITE VACCINES AGAINST CONTAGIOUS BRONCHITIS, METHOD FOR THEIR PREPARATION AND VIRUS STRAIN OF CONTAGIOUS BRONCHITIS.
ES8307499A1 (en) Vaccine against foot-and-mouth disease and colibacillosis, and process for preparing it.
FI910405A0 (en) PROCEDURE FOR THE FRAMSTATION OF EPIMERFRIA SOCKERAL ALCOHOL AND GROUP XYLITOL, SORBITOL (D-GLUKITOL), 4-O-B-D-GALACTOPYRANOSYL-D-GLUCITOL OCH 4-O-A-D-GLUCOPYRAN